Literature DB >> 28758887

Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors.

Stephen M Stahl.   

Abstract

Unravelling the mystery of dopamine neurotransmission, especially at its 3 most clinically relevant receptors, D3, D2, and D1, helps explain the pathophysiology of numerous psychiatric and neurologic symptoms in various CNS disorders that are theoretically caused by dysregulation of this neurotransmitter.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28758887     DOI： 10.1017/S1092852917000426

Source DB:  PubMed          Journal:  CNS Spectr        ISSN： 1092-8529            Impact factor:   3.790


  5 in total

Review 1.  Valbenazine for the Treatment of Adults with Tardive Dyskinesia.

Authors:  Harshit Gupta; Alycee R Moity; Allison Jumonville; Sarah Kaufman; Amber N Edinoff; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-18

Review 2.  Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy.

Authors:  Leslie Citrome
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-05       Impact factor: 2.570

3.  Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies.

Authors:  Réka Csehi; Zsófia Borbála Dombi; Barbara Sebe; Mária Judit Molnár
Journal:  Front Psychiatry       Date:  2022-03-17       Impact factor: 4.157

4.  Editorial: Novel antipsychotics within and beyond clinical trials: The treatment of overlapping psychiatric disorders with D3-D2 partial agonists.

Authors:  György Németh; Réka Csehi
Journal:  Front Psychiatry       Date:  2022-09-28       Impact factor: 5.435

Review 5.  The role of dopamine receptors in lymphocytes and their changes in schizophrenia.

Authors:  M A Penedo; T Rivera-Baltanás; D Pérez-Rodríguez; J Allen; A Borrajo; D Alonso-Crespo; C Fernández-Pereira; M Nieto-Araujo; S Ramos-García; C Barreiro-Villar; H J Caruncho; J M Olivares; R C Agís-Balboa
Journal:  Brain Behav Immun Health       Date:  2021-01-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.